Chemical industry – Page 38
-
NewsExplainer: the carbon dioxide crisis
Low stocks of carbon dioxide are causing problems for the food industry. So what’s really going on?
-
-
BusinessGene therapy gathers pace
Sarah Houlton charts the evolution, challenges and opportunities of cell and gene therapy
-
BusinessUbe’s management pays for lax quality checks
Japanese chemical maker announces that ‘quality-related improprieties’ were detected in 24 of its products, including low-density polyethylene
-
NewsFears that US 'right to try' law could put patients at risk
Legislation will give terminally ill patients the option of taking medicines that have had little testing
-
BusinessBayer–Monsanto merger momentum
US antitrust regulators approve Bayer’s $66bn takeover of Monsanto, conditional on the company offloading $9bn in assets
-
BusinessUS chemical safety agency wants Arkema disaster to spark real change
Industry guidance is needed to help hazardous chemical facilities better prepare for extreme weather events like flooding, the CSB warns
-
BusinessUS sanctions threaten Iran–Europe petrochemical ties
Companies review their options after Trump administration’s withdrawal from nuclear deal
-
BusinessRural power champion
Clementine Chambon is the 2018 Chemistry World Entrepreneur of the Year for her work using bioenergy to solve environmental, social and gender challenges in rural India
-
NewsJim Ratcliffe, head of UK chemical giant Ineos, tops Sunday Times rich list
A net worth of more than £21 billion makes chemical engineer UK’s richest person
-
BusinessUS senators launch probe of Novartis’ payments to Trump lawyer
Congress demands info from Novartis about its $1.2m in outflows to Michael Cohen, just as it was negotiating payments for its cancer drug
-
BusinessTrump lays out plan to slash drug costs
White House strategy to reduce pharmaceutical prices faces backlash from the industry, which cautions against the ‘far-reaching’ proposals
-
BusinessTakeda set to swallow Shire
Shire’s US revenue and rare diseases portfolio grab Japanese firm’s attention
-
ArticleAre polymer medicines viable therapeutics?
Combining small-molecule medicines with polymers could offer big rewards for pharmaceutical researchers
-
ArticleThe dark side of chemical patents
Unloved, ignored and misunderstood but could all that change?
-
FeatureUnderstanding Alzheimer’s
After hundreds of failed drug candidates, James Mitchell Crow asks if this is the last roll of the dice for the amyloid theory of Alzheimer’s disease
-
BusinessBig business computing
Chemical and oil firms are using supercomputers to improve every part of their operations. Angeli Mehta reports
-
Feature3D printing in pharma
Nina Notman explores how 3D printing is carving out a niche for itself in the pharmaceutical industry
-
BusinessChemicals caught in the middle as tariffs loom
America’s chemicals and plastics industry stands to lose $5bn if US–China dispute escalates
-
BusinessDeal protects world’s biggest selling drug from biosimilar erosion
AbbVie and Samsung Bioepis resolve patent litigation over arthritis drug Humira